ACTU
Actuate Therapeutics, Inc. Common stock
NASDAQ: ACTU · HEALTHCARE · BIOTECHNOLOGY
$2.88
-0.69% today
Updated 2026-04-29
Market cap
$68.29M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.06
Dividend yield
—
52W range
$2 – $12
Volume
0.1M
WallStSmart proprietary scores
20
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$13.50
+368.75%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-3.74M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-20.16M | $-24.74M | $-27.29M | $-22.23M | $-4.55M |
| EPS | — | — | — | — | $-1.06 |
| Free cash flow | $-17.79M | $-21.63M | $-21.84M | $-19.21M | $-3.74M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Actuate Therapeutics, Inc. Common stock trades at $2.88. Our Smart Value Score of 20/100 indicates the stock is weak.
Frequently asked questions
What is Actuate Therapeutics, Inc. Common stock's stock price?
Actuate Therapeutics, Inc. Common stock (ACTU) trades at $2.88.
Is Actuate Therapeutics, Inc. Common stock overvalued?
Smart Value Score 20/100 (Grade F, Strong Sell).
What is the price target of Actuate Therapeutics, Inc. Common stock (ACTU)?
The analyst target price is $13.50, representing +368.8% upside from the current price of $2.88.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-554.00%
Beta—
50D MA$2.76
200D MA$5.73
Shares out0.02B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—